Research Insight
Research Insight
Novartis BAF312 reduces the risk of disability progression in phase III study in secondary patients
EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in...
Research Insight
Merck to Develop Next-Generation Purification Processes with International Vaccine Institute
Merck, a leading science and technology company, has entered a research agreement with the International Vaccine Institute (IVI) of Seoul, South Korea to help develop...
Research Insight
Johnson & Johnson Pharmaceutica NV Idylla Ebola Virus Triage Test Granted Emergency Use Authorizatio
Johnson & Johnson’s commitment to combat Ebola, Janssen Pharmaceutica NV announced that the Idylla™ Ebola Virus Triage Test (Idylla™ EBOV Test) was granted Emergency Use...
Research Insight
Bayer collaborates with US NSAB Project Investigate Additional Adjuvant Therapy in Colon Cancer
Bayer and the U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP), a leading clinical trials cooperative group, are collaborating on a new Phase III...
Research Insight
Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated wi
Following the recommendation of an independent Data Monitoring Committee (DMC), Bayer is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated...
Research Insight
Edwards Lifesciences’ Philanthropy Impacts 200,000 Underserved Patients Through Every Heartbeat Matt
Edwards Lifesciences Corporation the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that reports from its philanthropic partners...
Research Insight
Horizon Discovery Introduces High Throughput Platform for Immuno-Oncology Research
Horizon Discovery Group plc, the world leader in the application of gene editing technologies including custom screening and specialized assay services,today announced the launch of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.